Aarti Pharmalabs Ltd

- There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. - The company has indicated ongoing and upcoming capex projects (e.g., Atali project with INR350-500 crores capex) being funded through existing resources and internal accruals. - Management highlighted reasonable debt levels and focus on EBITDA and PAT growth but did not specify raising new funds. - The discussions revolve around optimizing existing capacities, backward integration, and capex funded from internal cash flows. - No direct references to equity issuance or fresh borrowings for expansion were made during the Q&A or management commentary sections.

- Growth capex of over INR 200 crores incurred in the last couple of years, with INR 130 crores capitalized on the Tarapur project. Ramp-up expected over next 1 to 1.5 years. - Atali, Gujarat Greenfield project: 80 acres acquired; first phase involves 400k reactor volume capacity, targeting API, intermediates, and CDMO/CMO projects. Completion expected in H2 FY25. - Additional capacity expansions include debottlenecking Xanthine plant from 4,000 to 5,000 tons per annum, with further debottlenecking planned. - Maintenance and EHS capex typically INR 50-60 crores per year. - Future capex plans include potential for 2-3 additional blocks at current API sites based on demand, with flexibility to scale as utilization improves. - Capital employed for backward integration to reduce imports and improve margins, especially to reduce dependence on China.

- Company expects revenue growth of 12%-17% over the next few years, reflecting a solid but moderated pace compared to past CAGR of ~18%-20% (Page 12). - Growth driven by expansion in three segments: Xanthine, API/intermediates, and CDMO/CMO businesses, with the latter poised for faster growth and higher margins (Pages 11-12). - CDMO/CMO segment anticipated to grow from ~6% contribution currently to potentially 15%+ in 3 years (Page 11). - Capacity expansions, including debottlenecking and new Atali project (completed by H2 FY25), will enable volume growth and new product commercializations (Pages 6, 11). - Despite pressure on Xanthine prices, volume increase and capacity expansion aim to maintain or improve absolute EBITDA (Pages 6, 10). - New product launches, about 40 developments annually, support sales growth alongside broadening customer base in innovator pharma and food/cosmetics (Pages 3, 13).

- Management expects EBITDA growth in FY24 to be around 10%-15%, with sustainable EBITDA margins near 20% ±2%. - Long-term top-line growth guidance is 12%-17% annually, with PAT growth potentially higher due to manageable debt levels. - The CDMO/CMO segment is anticipated to grow and contribute over 10% to overall business in FY24, driving margin improvement. - Capacity expansions, including de-bottlenecking xanthine production and the Atali Greenfield project (completion expected H2 FY25), support growth. - Revenue growth may moderate due to price corrections in segments like Xanthine, but absolute EBITDA and profits are expected to improve through volume increases and operational efficiencies. - R&D expenditure remains stable, fueling product filings and innovation, which should contribute to longer-term earnings growth.

- Specific current or expected order book or pending orders details were not explicitly stated in the transcript. - Management highlighted ongoing growth with projects like Atali (expected completion H2 FY25) aimed at capacity expansion. - Focus is on increasing tonnage and backward integration to meet demand and maintain margins. - The CMO/CDMO segment is expected to grow significantly, possibly increasing from 6% to 15% contribution over the next three years. - The company is actively commercializing new products each year, aiming to file around 40 DMFs per year, with 40 filed to date as of FY23. - Inventories have increased but management expects these to be sold in upcoming quarters, indicating active order fulfillment underway. - Overall, the company expects stable or growing EBITDA and is optimistic about future order growth tied to capacity expansion and product pipeline.